Physician profile
Gurdeep Singh
NPI 1982837613
$759.12
in general payments reported to CMS, 2019-2025
16 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2021: $116 · 2022: $119 · 2023: $123 · 2024: $38.68 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $223.12 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $121.43 | 2023 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $100.44 | 2021 | |
| Janssen Biotech, INC. | $94.29 | 2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $29.19 | 2019 | |
| Amgen INC. | $28.02 | 2019 | |
| Pfizer INC. | $25.31 | 2019 | |
| Ibsa Pharma INC. | $17.95 | 2024 | Licart, Tirosint |
| Mannkind Corporation | $17.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.77 | 2021 | |
| Insulet Corporation | $15.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.03 | 2019 | |
| Cequr Corporation | $14.74 | 2023-2025 | Cequr Simplicity |
| Radius Health, INC. | $14.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.57 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurdeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.